BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor that is unresponsive to currently available therapies or for which no known effective therapy exists * Overexpressing HER-2-neu (2+ or 3+) by immunohistochemistry or fluorescent in situ hybridization * Clinically or radiologically evaluable disease * No carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal disease * At least 8 weeks since prior therapy for prior brain parenchymal disease and asymptomatic off corticosteroids * Performance status - ECOG 0-2 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.8 mg/dL * ALT and AST no greater than 1.5 times upper limit of normal (ULN) * Creatinine no greater than 1.5 times ULN * No uncontrolled or significant cardiovascular disease * No myocardial infarction within the past 6 months * No prior clinically significant atrial or ventricular arrhythmias * No prior second or third degree heart block * No ischemic heart disease requiring medication * No congestive heart failure * Corrected QT interval no greater than 450 milliseconds by electrocardiogram * Ejection fraction at least lower limit of normal by MUGA scan * No uncontrolled or significant pulmonary disease * No active unresolved infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study * At least 4 weeks since prior immunotherapy, including trastuzumab (Herceptin), and recovered * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * No anthracyclines for at least 22 weeks after completion of study therapy * No other concurrent chemotherapy * Concurrent hormone replacement therapy allowed * No other concurrent hormonal therapy * At least 4 weeks since prior radiotherapy and recovered * No prior radiotherapy to more than 25% of the bone marrow-containing skeleton * No concurrent radiotherapy * At least 4 weeks since prior investigational agents and recovered * At least 7 days since prior known substrates of cytochrome P450-3A4 (CYP3A4) * At least 7 days since prior parenteral antibiotics * No concurrent substrates of CYP3A4 * No concurrent parenteral antibiotics * No other concurrent experimental medications